Refine
H-BRS Bibliography
- yes (53) (remove)
Departments, institutes and facilities
- Fachbereich Angewandte Naturwissenschaften (53) (remove)
Document Type
- Article (27)
- Conference Object (18)
- Part of a Book (4)
- Conference Proceedings (1)
- Patent (1)
- Preprint (1)
- Report (1)
Year of publication
- 2017 (53) (remove)
Keywords
- GC/MS (3)
- stem cells (3)
- Analytical pyrolysis (2)
- Biomineralization (2)
- Enzyme activity (2)
- Explosives (2)
- Fatty acid metabolism (2)
- AMT (1)
- ATR-FTIR (1)
- Additives (1)
Multiple myeloma is the second most common hematological malignancy. Despite all the progress made in treating multiple myeloma, it still remains an incurable disease. Patients are left with a median survival of 4-5 years. The combined treatment of multiple myeloma with histone deacetylase inhibitors and cytokine-induced killer cells provides a promising targeted treatment option for patients. This study investigated the impact of a combined treatment compared to treatment with histone deacetylase inhibitors. The experiments revealed that a treatment with histone deacetylase (HDAC) inhibitors could reduce cell viability to 59% for KMS 18 cell line and 46% for the U-266 cell line. The combined treatment led to a decrease of cell viability to 33% for KMS 18 and 27% for the U-266 cell line, thus showing a significantly better efficacy than the single treatment.